|
Amylose
|
DB15216 |
[Amylose is under investigation in clinical trial NCT01027325 (Resistant Starch Insulin Sensitivity Trial).] |
|
KRN-5500
|
DB15215 |
[KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).] |
|
Pozelimab
|
DB15218 |
[Pozelimab is under investigation in clinical trial NCT03115996 (Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers).] |
|
Gastric inhibitory polypeptide
|
DB15217 |
[Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).] |
|
Pemafibrate
|
DB15212 |
[Pemafibrate is under investigation in clinical trial NCT03350165 (A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)).] |
|
Duvortuxizumab
|
DB15211 |
[Duvortuxizumab is under investigation in clinical trial NCT02743546 (Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma).] |
|
BMS-986104
|
DB15214 |
[BMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects).] |
|
25-desacetylrifapentine
|
DB15213 |
[25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).] |
|
Chlorotoxin
|
DB15210 |
[Chlorotoxin is under investigation in clinical trial NCT00733798 (A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma).] |
|
Formic Acid Benzyl Ester
|
DB04569 |
|
|
3,5-Difluoroaniline
|
DB03238 |
|
|
3',5'-Dinitro-N-Acetyl-L-Thyronine
|
DB03239 |
|
|
IT-101
|
DB05899 |
[IT-101 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound camptothecin. ] |
|
Chromophore (Gly-Tyr-Gly)
|
DB04567 |
|
|
(2s)-4-(Beta-Alanylamino)-2-Aminobutanoic Acid
|
DB03236 |
|
|
2,3-Dihydroxy-5-Oxo-Hexanedioate
|
DB03237 |
|
|
5-Aminoimidazole Ribonucleoside
|
DB04568 |
|
|
CERE-110
|
DB05898 |
[CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system. This drug is developed by Ceregene and currently under phase I of clinical trial.] |
|
rhIGFBP-3
|
DB05897 |
[rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed and is currently under phase I of the clinical trail.] |
|
4-(Acetylamino)-3-[(Hydroxyacetyl)Amino]Benzoic Acid
|
DB04565 |
|
